Real-time enrollment status for this relapsed or refractory multiple myeloma clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 2:42 AM UTC
| NCT Number | NCT07681596 |
| Recruiting Status | Recruiting |
| Condition | Relapsed or Refractory Multiple Myeloma |
| Phase | PHASE1 |
| Target Enrollment | 101 participants |
| Active Locations | 10 sites in the US |
| Sponsor | AstraZeneca |
| Last Updated on CT.gov | August 27, 2026 (Yesterday) |
As of August 28, 2026: Clinical trial NCT07681596 is currently recruiting participants. This phase1 study for relapsed or refractory multiple myeloma is actively seeking new participants at 10 locations across the United States. The study is sponsored by AstraZeneca. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07681596 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 10 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07681596 was last updated Yesterday (August 27, 2026). HelloStudys verifies this status automatically.